GlassScriptPhysician profile
Tamara Lynn Moore
NPI 1497011001
$733.33
in general payments reported to CMS, 2019-2025
23 companies · $131 in 2025
The $131 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $144 · 2020: $54.81 · 2021: $71.65 · 2022: $114 · 2023: $144 · 2024: $73.10 · 2025: $131.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $321 · Long Term Medical Supply Or Device Loan: $27.43.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $320.52 |
| Long Term Medical Supply Or Device Loan | $27.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $118.39 | 2022-2023 | Azstarys |
| Pfizer INC. | $90.78 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $56.64 | 2019-2025 | Gardasil 9, Vaqta, Vaxelis |
| Takeda Pharmaceuticals U.S.A., INC. | $56.59 | 2020-2021 | |
| Collegium Pharmaceutical, INC. | $34.78 | 2025 | Jornay Pm |
| Vanda Pharmaceuticals INC. | $33.00 | 2023 | Hetlioz |
| Shire North American Group INC | $32.52 | 2019 | |
| Neos Therapeutics, LP | $29.88 | 2019 | |
| Alk-Abello, INC | $27.92 | 2025 | Neffy |
| Supernus Pharmaceuticals, INC. | $27.60 | 2023 | Qelbree |
| Baxter Healthcare | $27.43 | 2024 | Hillrom - Audioscope 3 |
| Verrica Pharmaceuticals INC. | $26.53 | 2024 | Ycanth |
| Ars Pharmaceuticals Operations, INC. | $19.78 | 2025 | Neffy |
| Ironshore Pharmaceuticals INC. | $19.14 | 2024 | |
| Glaxosmithkline, LLC. | $17.59 | 2025 | Bexsero |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $17.45 | 2022 | |
| Novartis Pharmaceuticals Corporation | $16.58 | 2019 | |
| Adlon Therapeutics L.P. | $16.09 | 2020 | |
| Sanofi Pasteur INC. | $15.53 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $13.66 | 2025 | Zoryve |
| Cumberland Pharmaceuticals, INC. | $12.67 | 2019 | |
| Arbor Pharmaceuticals, INC. | $11.55 | 2019 | |
| Aytu Biopharma, INC. | $11.23 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tamara Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.